These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 7608324)
41. Hormone replacement and cancer. Barrett-Connor E Br Med Bull; 1992 Apr; 48(2):345-55. PubMed ID: 1450874 [TBL] [Abstract][Full Text] [Related]
42. Estrogens, progestins and breast cancer risk in post-menopausal women: state of the ongoing controversy in 1992. Sitruk-Ware R Maturitas; 1992 Oct; 15(2):129-39. PubMed ID: 1470045 [TBL] [Abstract][Full Text] [Related]
43. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer. van Leeuwen FE Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500 [TBL] [Abstract][Full Text] [Related]
44. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785 [TBL] [Abstract][Full Text] [Related]
45. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy. Genazzani AR; Gadducci A; Gambacciani M Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941 [TBL] [Abstract][Full Text] [Related]
50. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis. Asi N; Mohammed K; Haydour Q; Gionfriddo MR; Vargas OL; Prokop LJ; Faubion SS; Murad MH Syst Rev; 2016 Jul; 5(1):121. PubMed ID: 27456847 [TBL] [Abstract][Full Text] [Related]
51. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women. Stephenson K; Neuenschwander PF; Kurdowska AK Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249 [TBL] [Abstract][Full Text] [Related]
52. Micronized progesterone and its impact on the endometrium and breast vs. progestogens. Gompel A Climacteric; 2012 Apr; 15 Suppl 1():18-25. PubMed ID: 22432812 [TBL] [Abstract][Full Text] [Related]
53. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Godsland IF Fertil Steril; 2001 May; 75(5):898-915. PubMed ID: 11334901 [TBL] [Abstract][Full Text] [Related]
55. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency. Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796 [TBL] [Abstract][Full Text] [Related]
56. Clinical use of progestins in the menopausal patient: dosage and duration. Gambrell RD J Reprod Med; 1982 Aug; 27(8 Suppl):531-8. PubMed ID: 7131446 [TBL] [Abstract][Full Text] [Related]
57. [Hormone replacement therapy in the climacteric]. Canto de Cetina TE Rev Invest Clin; 1995; 47(1):49-61. PubMed ID: 7777716 [TBL] [Abstract][Full Text] [Related]
58. Cardiovascular benefits of estrogen replacement therapy. Ross RK; Paganini-Hill A; Mack TM; Henderson BE Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1301-6. PubMed ID: 2655453 [TBL] [Abstract][Full Text] [Related]
59. The effect of hormone replacement therapy on the levels of serum lipids, apolipoprotein AI, apolipoprotein B and lipoprotein (a) in Turkish postmenopausal women. Bayrak A; Aldemir DA; Bayrak T; Corakçi A; Dursun P Arch Gynecol Obstet; 2006 Aug; 274(5):289-96. PubMed ID: 16810536 [TBL] [Abstract][Full Text] [Related]
60. The impact of micronized progesterone on breast cancer risk: a systematic review. Stute P; Wildt L; Neulen J Climacteric; 2018 Apr; 21(2):111-122. PubMed ID: 29384406 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]